IP Library › Granted Patent US 12,421,538
Granted Patent B2
US 12,421,538 · App. 18/430,247 · Granted Sep 23, 2025

Quantitative assessment for cap efficiency of messenger RNA

Inventors: Frank Derosa (Lexington, MA); Anusha Dias (Lexington, MA); Michael Heartlein (Lexington, MA)
Assignee: TRANSLATE BIO, INC.
C12Q1/6804
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,538
App. No.
18/430,247
Granted
Sep 23, 2025
Kind
B2
Abstract

The present invention provides, among other things, methods of quantitating mRNA capping efficiency, particularly mRNA synthesized in vitro. In some embodiments, methods according to the present invention comprise providing an mRNA sample containing capped and uncapped mRNA, providing a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA, and quantitatively determining the amount of the complex as compared to a control, thereby quantifying mRNA capping efficiency.

Claims (38)

1. A method of quantifying mRNA capping efficiency, the method comprising:

a) contacting an mRNA sample comprising capped mRNA with a cap specific binding substance under conditions that permit the formation of a complex between the cap specific binding substance and the capped mRNA; and

b) quantitatively determining the amount of the complex as compared to a standard curve prepared using a number of samples of known cap concentration, thereby quantifying mRNA capping efficiency.

2. The method of claim 1 , wherein the cap has a structure of formula I:

wherein,

B is a nucleobase;

R 1 is selected from a halogen, OH, and OCH 3 ;

R 2 is selected from H, OH, and OCH 3 ;

R 3 is CH 3 , CH 2 CH 3 , CH 2 CH 2 CH 3 or void;

R 4 is NH 2 ;

R 5 is selected from OH, OCH 3 and a halogen;

n is 1, 2, or 3; and

M is a nucleotide of the mRNA.

3. The method of claim 2 , wherein the nucleobase is guanine.

4. The method of claim 1 , wherein the cap is a m 7 G cap with a structure of formula II:

wherein,

R 2 is H or CH 3 ;

R 4 is NH 2 ;

R 5 is OH or OCH 3 ;

R 6 is H or CH 3 ; and

M is a nucleotide of the mRNA.

5. The method of claim 1 , wherein the cap specific binding substance is a cap specific binding protein selected from the group consisting of eukaryotic initiation factor 4E (eIF-4E), nuclear cap-binding protein subunit 1, nuclear cap-binding protein subunit 2, and nuclear cap-binding complex.

6. The method of claim 1 , wherein the cap specific binding substance is a cap specific antibody.

7. The method of claim 6 , wherein the cap specific binding substance is an anti-m 7 G antibody.

8. The method of claim 1 , wherein the step of quantitatively determining the amount of the complex comprises measuring a detectable signal associated with the complex.

9. The method of claim 8 , wherein the detectable signal is a fluorescent signal, a colorimetric signal or a radioactive signal.

10. The method of claim 1 , wherein the samples of known cap concentration comprise an mRNA sample with a pre-determined amount of capped mRNA.

11. The method of claim 1 , wherein the samples of known cap concentration comprise a predetermined amount of synthesized cap.

12. The method of claim 1 , wherein quantifying mRNA capping efficiency comprises quantifying the absolute amount of capped mRNA in the mRNA sample.

13. The method of claim 1 , wherein quantifying mRNA capping efficiency comprises quantifying the percentage of capped mRNA in the mRNA sample.

14. The method of claim 1 , wherein the method further comprises a step of capturing the mRNA on a substrate.

15. The method of claim 14 , wherein the mRNA is captured by a poly-T oligo that binds to the poly-A tail of the mRNA.

16. The method of claim 14 , wherein the mRNA is captured by a poly-A binding protein or antibody.

17. The method of claim 14 , wherein the substrate is a microplate, magnetic bead, particle, polymeric bead, chromatographic resin, filter paper, nitrocellulose, diazocellulose, glass, latex, polystyrene, polyvinylchloride, propylene, polyethylene, dextran, Sepharose, agar, starch, nylon, silica gel, or hydrogel.

18. The method of claim 14 , wherein the substrate is coated with avidin or streptavidin.

19. The method of claim 18 , wherein the mRNA is captured by a poly-oligo that binds to the poly-A tail of the mRNA or by a poly-A binding protein or antibody, and wherein the poly-T oligo or the poly-A binding protein or antibody is biotinylated.

20. The method of claim 1 , wherein the mRNA sample is synthesized in vitro.

21. The method of claim 1 , wherein the mRNA sample comprising capped mRNA is provided in an amount less than 500 ng.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: HEARTLEIN, MICHAEL; DEROSA, FRANK; DIAS, ANUSHA
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 066331/0718 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2024
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 066487/0384 →
CHANGE OF NAME Recorded Feb 1, 2024
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 066487/0743 →
Continuity (5)
Continuation 17325092 · May 19, 2021
Continuation 16744985 · Jan 16, 2020
Continuation 14775844
Provisional Application 61784253 · Mar 14, 2013
Related Publication 20240417774A1 · Dec 19, 2024
References Cited (47)
US 9970047B2 · Heartlein et al. · 2018 [cited by applicant]
US 10626439B2 · Heartlein et al. · 2020 [cited by applicant]
US 11104934B2 · Heartlein et al. · 2021 [cited by applicant]
US 11365437B2 · Heartlein et al. · 2022 [cited by applicant]
US 11920182B2 · Heartlein · 2024 [cited by examiner]
US 20020197622A1 · McDevitt et al. · 2002 [cited by applicant]
US 20050053942A1 · Kauppinen et al. · 2005 [cited by applicant]
US 20100035249A1 · Hayashizaki et al. · 2010 [cited by applicant]
US 20120251618A1 · Schrum et al. · 2012 [cited by applicant]
US 20160002705A1 · Heartlein et al. · 2016 [cited by applicant]
US 20160032356A1 · Heartlein et al. · 2016 [cited by applicant]
US 20180291425A1 · Heartlein et al. · 2018 [cited by applicant]
US 20200318156A1 · Heartlein et al. · 2020 [cited by applicant]
US 20220364145A1 · DeRosa et al. · 2022 [cited by applicant]
WO 2017149139A1 · 2017 [cited by applicant]
WO 2019207060A1 · 2019 [cited by applicant]
Tilkorn, A. (Authorized Officer), Written Opinion of the International Searching Authority for PCT/US2014/027587 dated Jul. 24, 2014, 4 pages. [cited by applicant]
Kore et al., “Synthesis and biological evaluation of trimethyl-substituted cap analogs”, Bioorganic & Medicinal Chemistry, 2008, vol. 18, No. 3, pp. 880-884. [cited by applicant]
Gall-Truchot, A. (Authorized Officer), International Search Report for PCT/US2014/027602 dated Jul. 28, 2014, 6 pages. [cited by applicant]
Tilkorn, A. (Authorized Officer), International Search Report for PCT/US2014/027587 dated Jul. 24, 2014, 6 pages. [cited by applicant]
Albers et al., “Analysis of mRNA 5′-Terminal Cap Structures and Internal N6-Methyladenosine by Reversed-Phase High-Performance Liquid Chromatography”, Analytical Biochemistry, 1981, vol. 113, pp. 118-123. [cited by applicant]
Nojima et al., “The Interaction between cap-binding complex and RNA export factor is required for intronless mRNA export”, Journal of Biological Chemistry, 2007, vol. 282, No. 21, pp. 15645-15651. [cited by applicant]
Tcherepanova et al., “Ectopic expression of a truncated CD40L protein from synthetic post-transcriptionally capped RNA in dendritic cells induces high levels of IL-12 secretion”, BMC Molecular Biology, 2008, 9:90, 13 pa… [cited by applicant]
Grudzien et al., “Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency”, RNA, 2004, vol. 10, No. 9, pp. 1479-1487. [cited by applicant]
Theus et al., “A Simple Assay for Determining the Capping Efficiencies of RNA Polymerases Used for In Vitro Transcription”, Biotechniques, 1990, vol. 9, No. 5, pp. 610-612 and 614-615. [cited by applicant]
McCracken et al., “5′-Capping enzymes are targeted to pre-mRNA by binding to the phosphorylated carboxy-terminal domain of RNA polymerase II”, Genes and Development, 1997, vol. 22, No. 24, pp. 3306-3318. [cited by applicant]
Gall-Truchot, A. (Authorized Officer), Written Opinion of the International Searching Authority for PCT/US2014/027602 dated Jul. 28, 2014, 6 pages. [cited by applicant]
Alton et al., “A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis”, No. 3.… [cited by applicant]
Jemielity et al., “Novel ‘anti-reverse’ cap analogs with superior translational properties”, RNA, 2003, vol. 9, No. 9, pp. 1108-1122. [cited by applicant]
Otsuka et al., “Identification of a cytoplasmic complex that adds a cap onto 5′-monophosphate RNA”, Molecular and Cellular Biology, 2009, vol. 29, No. 8, pp. 2155-2167. [cited by applicant]
Kore et al., “Synthesis and evaluation of 2′-O-allyl substituted dinucleotide cap analog for mRNA translation”, Bioorganic & Medicinal Chemistry, 2010, vol. 18, No. 22, pp. 8061-8065. [cited by applicant]
Galipon et al., “Stress-induced IncRNAs evade nuclear degradation and enter the translational machinery”, Genes to Cells, 2013, vol. 18, No. 5, pp. 353-368. [cited by applicant]
US Notice of Allowance dated Feb. 22, 2022 for U.S. Appl. No. 15/936,293, 13 pages. [cited by applicant]
US Notice of Allowance dated Jan. 8, 2018 for U.S. Appl. No. 14/775,846, 8 pages. [cited by applicant]
US Office Action dated Mar. 19, 2020 for U.S. Appl. No. 15/936,293, 11 pages. [cited by applicant]
US Office Action dated Jun. 2, 2017 for U.S. Appl. No. 14/775,846, 16 pages. [cited by applicant]
US Office Action dated Feb. 26, 2021 for U.S. Appl. No. 15/936,293, 13 pages. [cited by applicant]
US Office Action dated Sep. 3, 2020 for U.S. Appl. No. 15/936,293, 14 pages. [cited by applicant]
US Office Action dated Oct. 4, 2017 for U.S. Appl. No. 14/775,846, 5 pages. [cited by applicant]
US Office Action dated Jul. 19, 2023 for U.S. Appl. No. 17/746,657, 15 pages. [cited by applicant]
Huang, Z., et al., “Single-nucleotide resolution of RNAs up to 59 nucleotides by high-performance liquid chromatography,” Analytical Biochemistry, 2013 (Available Online Dec. 27, 2012), vol. 435, pp. 35-43. [cited by applicant]
Wisniewski, M., et al., “Substrate Requirements for Secondary Cleavage by HIV-1 Reverse Transcriptase RNase H,” The Journal of Biological Chemistry, 2002 (Originally Published Online May 21, 2002), vol. 277, No. 32, pp.… [cited by applicant]
Moteki, S., et al., “Functional Coupling of Capping and Transcription of mRNA”, Molecular Cell, 2002, vol. 10, No. 3, pp. 559-609. [cited by applicant]
Office Action dated Aug. 25, 2023 for corresponding European Patent Application No. 18207398.1, 5 pages. [cited by applicant]
Anonymous: “Monoclonal mouse antibody against m3G-cap/m7G-cap”, Synaptic Systems GmbH Retrieved from the Internet: URL:https://www.sysy.com/products/cap/facts-201011.pbp, 2 pages. [cited by applicant]
Luhrmann et al., “Isolation and characterization of rabbit anti-m227G antibodies”, Nucleic Acids Research, 1982, vol. 10, No. 22, pp. 7103-7113. [cited by applicant]
Meredith et al., “Isolation and characterization of rabbit anti-m7G-5′-P antibodies of high apparent affinity”, Nucleic Acids Research, 1979, vol. 6, No. 6, pp. 2179-2191. [cited by applicant]